Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study
about
Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitorsTreatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.Current and future approaches for control of graft-versus-host disease.Aspergillus infections in transplant recipients.Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantationDifferent tumor necrosis factor α antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice.Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Emerging therapies for graft-versus-host disease.Acute graft versus host disease.Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification.Novel approaches in GVHD therapy.Recent advances in the treatment of graft-versus-host disease.Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes.Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy.Emerging fungal diseases.The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy.Current approaches to diagnosis and treatment of invasive aspergillosis.Implications of TNF-α in the pathogenesis and management of GVHDEtanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.Management of acute graft-versus-host disease.Zygomycosis--current epidemiological aspects.Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.Prevention and treatment of acute GvHD.Invasive mold infections: recent advances in management approaches.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.Immune response to Aspergillus fumigatus in compromised hosts: from bedside to bench.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?Tumor necrosis factor biologics beyond psoriasis in dermatology.Voriconazole in clinical practice.State-of-the-art acute and chronic GVHD treatment.Graft Versus Host Disease After Liver Transplantation in Adults: A Case series, Review of Literature, and an Approach to Management.Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole.Oral beclomethasone dipropionate in gastrointestinal graft-versus-host disease.Advances in the clinical management of GVHD.Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation.Absence of host tumor necrosis factor receptor 1 attenuates manifestations of idiopathic pneumonia syndrome.Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marr
P2860
Q29302324-823BF088-94F8-489B-A094-882CDAE6A333Q33213561-C55209AD-1490-4099-B852-5815AB5FE5B5Q33642625-34E37ADE-DEDA-46F5-BEEC-655926394D16Q33719294-A6F8E494-6A3C-4106-ADA9-061F450AC4FAQ33910076-26EB585A-1058-4538-B172-AE8F29EFC6A6Q33927362-C259D364-78F1-4343-9BD1-F8A995ECEC2DQ34441886-C72906D8-D1AC-4BD0-99FA-0C33135FCD55Q34532546-BBF6DFFC-CB22-432C-A7F6-AB9797E43948Q35602633-57C95ECB-924F-4762-832C-9C0F58AA34B5Q36059671-2D5CA4A1-B8E8-4652-9E5F-158AF02C140BQ36071289-BF748EE7-2E31-4643-A797-CDAA562E914EQ36090227-EB065DBD-B440-48FB-A161-188436D7CFB9Q36148596-7137F1F2-18A8-4511-AD0E-F4FA6526BDBAQ36194610-2B3C5AEE-5715-421C-BECD-3FA4CF1C594EQ36194915-75A96792-DA28-403E-8A28-88A00CE856B5Q36199785-21B79D4B-24E9-421A-AED0-9C3443BA403EQ36344173-DEF4F6F6-019E-45A3-BCBB-E1D49D50E27FQ36357893-6ED8CCE8-5EBA-4BBF-A1EC-AEC4D3384841Q36370782-65128CAF-8E71-4F7C-9F4D-C5FD683A2C1DQ36615576-37E4BD95-E638-4B91-B7F2-37FA2EC11229Q36773002-F5E66D2C-126E-48EE-9ED7-EF4B75E2C6C0Q36774266-E59EDABF-C21B-4ADD-8607-5046E7BE7A57Q37015953-6FF50A5D-DA33-446A-A5A4-31DEE85652A9Q37188487-2BD51777-4D13-4948-ABDD-D68555F052A9Q37428946-1CAB14D5-8043-4D0A-9531-9257F07F0B31Q37810286-0C5A0079-F4C1-468F-9B7C-17C7FD49DF21Q37821488-75344944-76AC-41A5-9BE5-0790AC5ED115Q37851519-0FEBE5E6-8F14-40A2-BB16-655D5FB065CDQ37866827-C9CA5B67-DF5C-4507-8A78-E79D112AC57DQ37886194-49092483-EFEA-4111-ADB0-9B31AEB0D881Q38061736-4080F609-7216-4091-98A3-00B090443E2FQ38416376-35845BF5-2748-4AF5-9113-B7E7545B5552Q38919897-74D5AE8C-1EB1-49A9-B98E-53730A17B2F5Q40795565-4C8018C2-3AEA-4DB8-AB34-B10D41B1B82BQ43061699-DD614E50-F6AC-46B5-9BD3-153F54F86F65Q43170920-127278C6-3205-46D1-96A2-7309D7445A89Q44791854-144EF593-42DC-4231-877F-C044C88E6931Q44973658-7AA2C78D-82BB-4595-AC92-37C3FD5045E1Q45193719-BE7E2D45-0554-437D-AE59-458762625E1FQ46584471-D8446EE4-1F46-40F6-8859-CC9E171B2FB1
P2860
Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study
description
im Juli 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 July 2003
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2003
@uk
name
Infliximab use in patients wit ...... ant recipients: a cohort study
@en
Infliximab use in patients wit ...... ant recipients: a cohort study
@nl
type
label
Infliximab use in patients wit ...... ant recipients: a cohort study
@en
Infliximab use in patients wit ...... ant recipients: a cohort study
@nl
prefLabel
Infliximab use in patients wit ...... ant recipients: a cohort study
@en
Infliximab use in patients wit ...... ant recipients: a cohort study
@nl
P2093
P1433
P1476
Infliximab use in patients wit ...... ant recipients: a cohort study
@en
P2093
Edwin P Alyea
Joseph H Antin
Michelle M Fahey
Robert J Soiffer
Stephanie J Lee
P304
P356
10.1182/BLOOD-2003-01-0267
P407
P577
2003-07-10T00:00:00Z